Clinuvel Pharmaceuticals Ltd (CUV)

Currency in AUD
10.65
-1.88(-15.00%)
Closed·
CUV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
CUV is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.5012.29
52 wk Range
9.4115.99
Key Statistics
Bid/Ask
11.18 / 10.72
Prev. Close
12.53
Open
12.29
Day's Range
10.5-12.29
52 wk Range
9.41-15.99
Volume
709.57K
Average Volume (3m)
109.79K
1-Year Change
-22.59%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CUV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.42
Upside
+129.26%
Members' Sentiments
Bearish
Bullish
ProTips
Impressive gross profit margins
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Clinuvel Pharmaceuticals Ltd Company Profile

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Employees
16
Market
Australia

Compare CUV to Peers and Sector

Metrics to compare
CUV
Peers
Sector
Relationship
P/E Ratio
16.2x−2.5x−0.6x
PEG Ratio
0.51−0.050.00
Price/Book
2.9x2.1x2.6x
Price / LTM Sales
6.9x12.5x3.3x
Upside (Analyst Target)
82.8%325.6%39.1%
Fair Value Upside
Unlock−7.5%5.4%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.42
(+129.26% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.77%
Dividend Yield
0.47%
Industry Median 2.06%
Annualised payout
0.05
Paid unevenly
5-Years Growth
+14.87%
Growth Streak

Earnings

Latest Release
Feb 26, 2025
EPS / Forecast
0.28 / 25.90
Revenue / Forecast
35.65M / 34.13M
EPS Revisions
Last 90 days

CUV Income Statement

People Also Watch

0.535
VAU
+0.94%
212.89
CSL
+0.09%
12.920
ORG
-0.54%
6.330
ILU
+1.44%
42.080
RMD
-3.00%

FAQ

What Stock Exchange Does Clinuvel Pharmaceuticals Trade On?

Clinuvel Pharmaceuticals is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Clinuvel Pharmaceuticals?

The stock symbol for Clinuvel Pharmaceuticals is "CUV."

What Is the Clinuvel Pharmaceuticals Market Cap?

As of today, Clinuvel Pharmaceuticals market cap is 529.10M.

What Is Clinuvel Pharmaceuticals's Earnings Per Share (TTM)?

The Clinuvel Pharmaceuticals EPS (TTM) is 0.77.

From a Technical Analysis Perspective, Is CUV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Clinuvel Pharmaceuticals Stock Split?

Clinuvel Pharmaceuticals has split 2 times.

How Many Employees Does Clinuvel Pharmaceuticals Have?

Clinuvel Pharmaceuticals has 16 employees.

What is the current trading status of Clinuvel Pharmaceuticals (CUV)?

As of 29 Aug 2025, Clinuvel Pharmaceuticals (CUV) is trading at a price of 10.65, with a previous close of 12.53. The stock has fluctuated within a day range of 10.50 to 12.29, while its 52-week range spans from 9.41 to 15.99.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.